Abstract:Repurposing identified Food and Drug Administration‐approved drug‐biomarker combinations with high sensitivity and specificity. In a real‐world dataset, repurposing identified novel drug‐biomarker combinations in patients who were ineligible for standard therapies or biomarker‐matched trials. Preliminary functional validation was demonstrated for two drug‐biomarker combinations. Using The Cancer Genome Atlas data, the potential scope of repurposing was identified. Purpose Systematic repurposing of approved medicines for another indication may accelerate drug development in oncology. We present a strategy combining biomarker testing with drug repurposing to identify new treatments for patients with advanced cancer. Methods Tumours were sequenced with the Illumina TruSight Oncology 500 (TSO‐500) platform or the FoundationOne CDx panel. Mutations were screened by two medical oncologists and pathogenic mutations were categorised referencing literature. Variants of unknown significance were classified as potentially pathogenic using plausible mechanisms and computational prediction of pathogenicity. Gain of function (GOF) mutations were evaluated through repurposing databases Probe Miner (PM), Broad Institute Drug Repurposing Hub (Broad Institute DRH) and TOPOGRAPH. GOF mutations were repurposing events if identified in PM, not indexed in TOPOGRAPH and excluding mutations with a known Food and Drug Administration (FDA)‐approved biomarker. The computational repurposing approach was validated by evaluating its ability to identify FDA‐approved biomarkers. The total repurposable genome was identified by evaluating all possible gene‐FDA drug‐approved combinations in the PM dataset. Results The computational repurposing approach was accurate at identifying FDA therapies with known biomarkers (94%). Using next‐generation sequencing molecular reports (n = 94), a meaningful percentage of patients (14%) could have an off‐label therapeutic identified. The frequency of theoretical drug repurposing events in The Cancer Genome Atlas pan‐cancer dataset was 73% of the samples in the cohort. Conclusion A computational drug repurposing approach may assist in identifying novel repurposing events in cancer patients with no access to standard therapies. Further validation is needed to confirm a precision oncology approach using drug repurposing.

High throughput in vivo phenotypic screening for drug repurposing: Discovery of MLR-1023 a novel insulin sensitizer and novel Lyn kinase activator with clinical proof of concept

In vivo phenotypic screening: clinical proof of concept for a drug repositioning approach

Phenotypic screening of low molecular weight compounds is rich ground for repurposed, on-target drugs

High-Throughput Methods for the Discovery of Small Molecule Modulators of Pancreatic Beta-Cell Function and Regeneration

Genetic and Pharmacological Interrogation of Cancer Vulnerability Using a Multiplexed Cell Line Screening Platform

The Discovery of New Inhibitors of Insulin-Regulated Aminopeptidase by a High-Throughput Screening of 400,000 Drug-like Compounds

Computational repurposing of oncology drugs through off‐target drug binding interactions from pharmacological databases

PHDs-seq: a Large-Scale Phenotypic Screening Method for Drug Discovery Through Parallel Multi-Readout Quantification

Integrated ML-Based Strategy Identifies Drug Repurposing for Idiopathic Pulmonary Fibrosis

Abstract 15297: Discovery and Preclinical Optimization of Selective ABCA1 Inducers as Multifunctional Therapeutic Candidates

Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens

The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes

A Miniaturized Cell-Based Fluorescence Resonance Energy Transfer Assay for Insulin-Receptor Activation

Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension

Novel Multiplexed High Throughput Screening of Selective Inhibitors for Drug-Metabolizing Enzymes Using Human Hepatocytes

AI-driven drug discovery: identification and optimization of ALDH3A1 selective inhibitors with nanomolar activity

A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus

Artificial Intelligence/Machine Learning-Driven Small Molecule Repurposing via Off-Target Prediction and Transcriptomics

Uncovering receptor-ligand interactions using a high-avidity CRISPR activation screening platform

A Study on Methodologies of Drug Repositioning Using Biomedical Big Data: A Focus on Diabetes Mellitus

High Throughput Sequencing Platform for Small Molecule Cancer Drug Discovery